<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Brain Neurosci Adv</journal-id>
<journal-id journal-id-type="iso-abbrev">Brain Neurosci Adv</journal-id>
<journal-id journal-id-type="publisher-id">BNA</journal-id>
<journal-id journal-id-type="hwp">spbna</journal-id>
<journal-title-group>
<journal-title>Brain and Neuroscience Advances</journal-title>
</journal-title-group>
<issn pub-type="epub">2398-2128</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32166183</article-id>
<article-id pub-id-type="pmc">7058221</article-id>
<article-id pub-id-type="doi">10.1177/2398212819858249</article-id>
<article-id pub-id-type="publisher-id">10.1177_2398212819858249</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A half century of γ-aminobutyric acid</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Smart</surname>
<given-names>Trevor G</given-names>
</name>
<xref ref-type="aff" rid="aff1-2398212819858249">1</xref>
<xref ref-type="corresp" rid="corresp1-2398212819858249"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Stephenson</surname>
<given-names>F Anne</given-names>
</name>
<xref ref-type="aff" rid="aff2-2398212819858249">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-2398212819858249"><label>1</label>Department of Neuroscience, Physiology and Pharmacology, University College London, London, UK</aff>
<aff id="aff2-2398212819858249"><label>2</label>UCL School of Pharmacy, University College London, London, UK</aff>
<author-notes>
<corresp id="corresp1-2398212819858249">Trevor G Smart, Department of Neuroscience, Physiology and Pharmacology, University College London, London WC1E 6BT, UK. Email: <email>t.smart@ucl.ac.uk</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>27</day>
<month>11</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<season>Jan-Dec</season>
<year>2019</year>
</pub-date>
<volume>3</volume>
<elocation-id>2398212819858249</elocation-id>
<history>
<date date-type="received">
<day>12</day>
<month>2</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2019</copyright-statement>
<copyright-year>2019</copyright-year>
<copyright-holder content-type="sage">SAGE Publications Ltd and British Neuroscience Association, unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses</copyright-holder>
<license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
<license-p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="http://www.creativecommons.org/licenses/by-nc/4.0/">http://www.creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page(<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>γ-aminobutyric acid has become one of the most widely known neurotransmitter molecules in the brain over the last 50 years, recognised for its pivotal role in inhibiting neural excitability. It emerged from studies of crustacean muscle and neurons before its significance to the mammalian nervous system was appreciated. Now, after five decades of investigation, we know that most neurons are γ-aminobutyric-acid-sensitive, it is a cornerstone of neural physiology and dysfunction to γ-aminobutyric acid signalling is increasingly documented in a range of neurological diseases. In this review, we briefly chart the neurodevelopment of γ-aminobutyric acid and its two major receptor subtypes: the γ-aminobutyric acid<sub>A</sub> and γ-aminobutyric acid<sub>B</sub> receptors, starting from the humble invertebrate origins of being an ‘interesting molecule’ acting at a single γ-aminobutyric acid receptor type, to one of the brain’s most important neurochemical components and vital drug targets for major therapeutic classes of drugs. We document the period of molecular cloning and the explosive influence this had on the field of neuroscience and pharmacology up to the present day and the production of atomic γ-aminobutyric acid<sub>A</sub> and γ-aminobutyric acid<sub>B</sub> receptor structures. γ-Aminobutyric acid is no longer a humble molecule but the instigator of rich and powerful signalling processes that are absolutely vital for healthy brain function.</p>
</abstract>
<kwd-group>
<kwd>GABA</kwd>
<kwd>GABA<sub>A</sub> receptor</kwd>
<kwd>GABA<sub>B</sub> receptor</kwd>
<kwd>inhibition</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>January-December 2019</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<p>γ-Aminobutyric acid (GABA) is widely known today as the most important inhibitory neurotransmitter in the mammalian central nervous system, controlling the excitability of neurons and determining the temporal activity profiles of neural networks. To understand how GABA achieved this prominence in brain function, and initially how difficult and controversial this appeared to the early neuroscience field, we need to travel back to just over 50 years ago, to a time when the concept of ‘chemical transmission’ was in its infancy, and only acetylcholine and catecholamines were acknowledged as transmitter molecules. During this period, little thought had been given to amino acids performing such a transmitter role.</p>
<sec id="section1-2398212819858249">
<title>What causes the inhibition of neurons?</title>
<p>The discovery of GABA in the nervous system was first made in the 1950s when studies on mammalian neurons were significantly outnumbered by the use of more accessible and easier to prepare invertebrate systems with their excitatory and inhibitory control of muscle movement. It was the work of <xref ref-type="bibr" rid="bibr46-2398212819858249">Stephen Kuffler (1954)</xref> and <xref ref-type="bibr" rid="bibr23-2398212819858249">Ernst Florey (1954)</xref> that promoted the use of crustacean preparations as particularly good assay systems for identifying neuroactive substances extracted from mammalian brain. One such inhibitory factor (termed ‘Factor I’) possessed similar inhibitory properties on smooth muscle to that subsequently demonstrated with GABA (<xref ref-type="bibr" rid="bibr25-2398212819858249">Florey and McLennan, 1959</xref>) and was later chemically identified as GABA (<xref ref-type="bibr" rid="bibr24-2398212819858249">Florey, 1991</xref>), even though Florey was sceptical as to whether GABA was actually a neurotransmitter. Identifying an endogenous substance from the mammalian brain, including its biosynthetic precursors (<xref ref-type="bibr" rid="bibr72-2398212819858249">Roberts and Frankel, 1950</xref>), and also characterising its properties on invertebrate preparations were an important step but it did not prove unequivocally that GABA was an important inhibitory neurotransmitter. Addressing the latter aspect was to take up a large proportion of the 1960s.</p>
</sec>
<sec id="section2-2398212819858249">
<title>The sixties – is GABA a neurotransmitter?</title>
<p>To award the status of ‘neurotransmitter’ to any molecule, the molecule has to fulfil a number of criteria. These have evolved over time and broadly include the following:</p>
<list id="list1-2398212819858249" list-type="order">
<list-item>
<p>The molecule must be present, concentrated within the presynaptic neuron, preferably in synaptic vesicles.</p>
</list-item>
<list-item>
<p>Synthetic enzymes should be present in presynaptic terminals for generating the molecule.</p>
</list-item>
<list-item>
<p>Axonal depolarisation should transiently release molecules in high concentration into the synaptic cleft in a Ca<sup>2+</sup>-dependent fashion.</p>
</list-item>
<list-item>
<p>Specific receptors that bind the molecule must be present on the postsynaptic cell membrane whose activation can be reproduced by exogenous application of the molecule to the preparation.</p>
</list-item>
<list-item>
<p>Enzymes and/or transporters should exist at the synapse to rapidly terminate the action of the molecule.</p>
</list-item>
</list>
<p>So in essence, in the early days of GABA research, its presence and release at synapses, and activation of postsynaptic receptors, was crucial for proving it was an inhibitory neurotransmitter. Providing solutions for the above conundrums took many years of the 1960s. Initial studies on cat spinal neurons using iontophoretic application of GABA showed promise and revealed inhibition of spiking activity (<xref ref-type="bibr" rid="bibr15-2398212819858249">Curtis et al., 1959</xref>), but despite this observation, GABA did not gain traction as a neurotransmitter and the inhibition was considered to be a non-specific effect. In the cerebral cortex, also using iontophoresis, <xref ref-type="bibr" rid="bibr44-2398212819858249">Krnjevic and Phillis (1963)</xref> demonstrated that GABA was an effective and rapidly acting inhibitor of neuronal excitation. Further studies on cortical neurons revealed that GABA hyperpolarised the membrane potential and caused a reduction in membrane resistance (<xref ref-type="bibr" rid="bibr45-2398212819858249">Krnjevic and Schwartz, 1967</xref>), both key features expected of an inhibitory neurotransmitter. Moreover, application of GABA to the cortex also occluded the hyperpolarising inhibitory postsynaptic potential (IPSP; <xref ref-type="fig" rid="fig1-2398212819858249">Figure 1</xref>), implying that GABA was indeed the inhibitory neurotransmitter (<xref ref-type="bibr" rid="bibr16-2398212819858249">Dreifuss et al., 1969</xref>; <xref ref-type="bibr" rid="bibr43-2398212819858249">Krnjevic, 2010</xref>). These findings indicated that GABA could reproduce the features of neuronal inhibition, but other criteria for a neurotransmitter remained unfulfilled at this time. The important aspect of terminating neurotransmitter action was eventually solved by the discovery of a GABA transporter (GAT) (uptake), which was proposed to be the main mode of inactivating the action of GABA at inhibitory synapses (<xref ref-type="bibr" rid="bibr33-2398212819858249">Iversen and Neal, 1968</xref>). Thus, towards the end of the sixties, GABA was becoming accepted as an inhibitory transmitter in the mammalian brain.</p>
<fig id="fig1-2398212819858249" orientation="portrait" position="float">
<label>Figure 1.</label>
<caption>
<p>GABA-mediated inhibitory postsynaptic potentials (IPSPs) recorded from neocortical neurons: (a) Hyperpolarizing IPSP with two superimposed current steps (I, top trace) deflecting the membrane potential (V, arrow, blue dotted line, lower trace) before the IPSP and then at the peak IPSP. Note the reduction in the voltage step size during the IPSP, which is indicative of increased membrane conductance caused by synaptic release of GABA and the opening of GABA ion channels. Red dotted lines indicate the extent of hyperpolarisation. (b) Application of GABA also produces a hyperpolarisation of the membrane with increased membrane conductance (note that both voltage steps are now equally reduced due to GABA application). Note also the occlusion of the IPSP. Data in (a) and (b) are modified after being taken from <xref ref-type="bibr" rid="bibr16-2398212819858249">Dreifuss et al (1969)</xref>.</p>
</caption>
<graphic xlink:href="10.1177_2398212819858249-fig1"></graphic>
</fig>
</sec>
<sec id="section3-2398212819858249">
<title>The seventies – GABA mapping and pharmacology</title>
<p>This new decade began with the important seminal discovery of a selective antagonist for GABA receptors, the plant alkaloid bicuculline (<xref ref-type="bibr" rid="bibr14-2398212819858249">Curtis et al., 1970</xref>; <xref ref-type="bibr" rid="bibr36-2398212819858249">Johnston, 2013</xref>). With such a selective compound, it became possible to pharmacologically isolate and analyse GABA-mediated inhibition in the nervous system. This discovery was facilitated by the use of a radiolabelled GABA agonist, [<sup>3</sup>H]-muscimol, which could label GABA<sub>A</sub> receptors in neuronal tissue, thus providing effective means to detect receptors in vitro (<xref ref-type="bibr" rid="bibr3-2398212819858249">Beaumont et al., 1978</xref>). Consequently, GABA was now becoming increasingly recognised as a major inhibitory neurotransmitter in the brain. The 1970s marked a period when many began to define the characteristics of the receptor through which GABA was acting to cause inhibition. For example, ligands such as anaesthetics (e.g. barbiturates) were shown to potentiate the action of GABA (<xref ref-type="bibr" rid="bibr79-2398212819858249">Scholfield, 1978</xref>, <xref ref-type="bibr" rid="bibr80-2398212819858249">1980</xref>), and most significant in terms of future therapeutics, the benzodiazepines appeared to act by potentiating GABA inhibition (<xref ref-type="bibr" rid="bibr30-2398212819858249">Haefely et al., 1975</xref>). In tandem with early pharmacological exploration, others started to map the extent of GABA-containing cells and processes in the spinal cord by using the GABA synthesising enzyme, glutamate decarboxylase (GAD) (<xref ref-type="bibr" rid="bibr1-2398212819858249">Barber et al., 1978</xref>), a procedure that is frequently used now in finding the locations of GABA-containing interneurons in the brain.</p>
</sec>
<sec id="section4-2398212819858249">
<title>The eighties and nineties – GABA receptors: their functional and structural diversity</title>
<p>Just prior to these final decades of the 1900s, most researchers simplistically thought there was a single receptor type for GABA and that the pharmacological outlook was relatively simple. To provide evidence for this view, however, required the biochemical identification of the GABA receptor protein, but this proved to be quite elusive as there were no sources rich in GABA receptor protein. However, two developments helped to mitigate this, including the use of larger mammalian brains (e.g. bovine) to provide sufficient starting material for protein purification and the concurrent serendipitous use of benzodiazepine affinity column purification techniques (<xref ref-type="bibr" rid="bibr86-2398212819858249">Sigel et al., 1982</xref>, <xref ref-type="bibr" rid="bibr87-2398212819858249">1983</xref>) to capture GABA receptor protein. These approaches led to the isolation of two different subunits termed α and β. Subsequent protein sequencing of the purified receptor and the use of selected peptide sequences to design oligonucleotide probes allowed the identification of (cloned) cDNAs encoding the α and β subunits. Significantly, these two subunits could be expressed outside the nervous system as a functional GABA receptor (<xref ref-type="bibr" rid="bibr78-2398212819858249">Schofield et al., 1987</xref>). This was achieved using a valuable heterologous expression vehicle, the <italic>Xenopus laevis</italic> oocyte, which was capable of expressing functional GABA<sub>A</sub> receptors when injected with appropriate mRNA, cRNAs or cDNAs (<xref ref-type="bibr" rid="bibr59-2398212819858249">Miledi et al., 1983</xref>; <xref ref-type="bibr" rid="bibr90-2398212819858249">Smart et al., 1983</xref>, <xref ref-type="bibr" rid="bibr91-2398212819858249">1987</xref>).</p>
<p>The primary sequence homology of these GABA α and β subunits clearly showed they belonged to a common class of receptors, which included nicotinic acetylcholine and glycine receptors. They were initially characterised by a structural signature, a Cys loop, which is identified by two cysteine residues that engage in a disulphide bond encapsulating a loop of 13 amino acids (<xref ref-type="bibr" rid="bibr2-2398212819858249">Barnard et al., 1987</xref>). From this structure, their name was derived – the Cys-loop receptors. Later, this family has been renamed as the pentameric ligand-gated ion channels and also includes serotonin type-3 receptors, Zn<sup>2+</sup> activated cation channel, invertebrate channels activated by glutamate, serotonin or GABA, and bacterial homologues, <italic>Gloeobacter violaceus</italic> (GLIC) and <italic>Erwinia chrysanthemi</italic> (ELIC). All the eukaryotic receptors in this family possess a Cys-loop motif, while the prokaryotic counterparts do not (<xref ref-type="bibr" rid="bibr89-2398212819858249">Smart and Paoletti, 2012</xref>).</p>
<p>Significantly, and surprisingly, given that GABA<sub>A</sub> receptor protein was purified by benzodiazepine affinity chromatography, the cloned αβ GABA receptor lacked sensitivity to benzodiazepines. This implied that other receptor subunits must exist to provide the full spectrum of pharmacological and physiological function. Indeed, this proved to be the case with the discovery of the γ subunit (<xref ref-type="bibr" rid="bibr70-2398212819858249">Pritchett et al., 1989</xref>), and from the basis of single α, β and γ subunits, molecular cloning studies rapidly expanded the GABA receptor subunit portfolio (<xref ref-type="bibr" rid="bibr82-2398212819858249">Seeburg et al., 1990</xref>), which eventually included new subunit families and some other families exhibiting multiple members, α(1–6), β(1–3), γ(1–3), δ, ε, π, θ and ρ(1–3), eventually totalling 19 subunits, without including the increased diversity that arises from RNA alternative splicing affecting α6, β2 and γ2 (<xref ref-type="bibr" rid="bibr54-2398212819858249">MacDonald and Olsen, 1994</xref>; <xref ref-type="bibr" rid="bibr83-2398212819858249">Sieghart, 1995</xref>; <xref ref-type="bibr" rid="bibr85-2398212819858249">Sigel and Steinmann, 2012</xref>; <xref ref-type="bibr" rid="bibr88-2398212819858249">Smart, 2015</xref>; <xref ref-type="bibr" rid="bibr92-2398212819858249">Stephenson, 1995</xref>).</p>
</sec>
<sec id="section5-2398212819858249">
<title>Core features of the pentameric receptor structure</title>
<p>Once the GABA<sub>A</sub> receptor genes were known and functional receptors could be expressed in cell lines for exploratory experiments, there followed a period of intense scrutiny of the GABA receptor’s structure and its functional properties. The pentameric ligand-gated receptor family retains a characteristic structural signature (<xref ref-type="bibr" rid="bibr19-2398212819858249">Ernst et al., 2005</xref>). They possess a large extracellular domain (ECD) that incorporates the neurotransmitter (orthosteric) binding site (<xref ref-type="bibr" rid="bibr52-2398212819858249">Lummis, 2009</xref>) located at interfaces between β<sup>+</sup>–α<sup>–</sup> subunits, and allosteric binding sites for modulators, such as the benzodiazepines at the α<sup>+</sup>–γ<sup>–</sup> subunit interface (<xref ref-type="bibr" rid="bibr84-2398212819858249">Sigel, 2002</xref>) and barbiturates at the γ<sup>+</sup>–α<sup>–</sup> interface (<xref ref-type="bibr" rid="bibr35-2398212819858249">Jayakar et al., 2015</xref>) (<xref ref-type="fig" rid="fig2-2398212819858249">Figure 2(a)</xref> and (<xref ref-type="fig" rid="fig2-2398212819858249">c</xref>)). The signature Cys loop is evident in all receptors and appeared to interact with residues in the transmembrane domain (TMD) M2-M3 region (<xref ref-type="fig" rid="fig2-2398212819858249">Figure 2(b)</xref>).</p>
<fig id="fig2-2398212819858249" orientation="portrait" position="float">
<label>Figure 2.</label>
<caption>
<p>Structural architectures of GABA<sub>A</sub> receptor subunits: (a) Representation of the GABA receptor β3 homomer crystal structure showing the extracellular domain (ECD) and transmembrane domain (TMD) as seen from the plane of the cell membrane (PDB, 4cof, <xref ref-type="bibr" rid="bibr60-2398212819858249">Miller and Aricescu, 2014</xref>). Each β3 subunit comprising the pentamer is shown in a different colour. Secondary structures are shown – β sheets in the ECD and α helices in the TMD. (b) A flattened and simplified schematic of a typical GABA<sub>A</sub> receptor subunit showing structures for the extracellular domain (ECD, β sheets), the transmembrane domain (TMD) with four α-helices, M1-M4, and the unknown structure of the intracellular domain (ICD) with phosphorylation sites (red circles). The key structures involved in receptor activation, loops 2, 7 and 9 are shown including loop C which is close to the GABA binding site. Modified from a schematic in <xref ref-type="bibr" rid="bibr89-2398212819858249">Smart and Paoletti, 2012</xref>. (c) Plan view of a GABA<sub>A</sub> receptor pentamer schematic showing subunit arrangement and the principal (+) and complementary (–) subunit interfaces as well as the position of the M1-M4 α-helices in the γ2 subunit only. GABA and benzodiazepine interfacial binding locations are shown.</p>
</caption>
<graphic xlink:href="10.1177_2398212819858249-fig2"></graphic>
</fig>
<p>A linker connects the ECD to the start of four α-helical TMDs (M1-M4, per subunit), of which the M2 subunit forms the lining of an ion channel pore that selects for anion (mostly Cl<sup>–</sup>) permeation (<xref ref-type="fig" rid="fig2-2398212819858249">Figure 2(b)</xref> and (<xref ref-type="fig" rid="fig2-2398212819858249">c</xref>)). This domain also incorporates a number of allosteric binding sites for a variety of ligands including loreclezole (<xref ref-type="bibr" rid="bibr96-2398212819858249">Wafford et al., 1994</xref>), neurosteroids (<xref ref-type="bibr" rid="bibr32-2398212819858249">Hosie et al., 2006</xref>) and some anaesthetics (<xref ref-type="bibr" rid="bibr26-2398212819858249">Franks, 2015</xref>). At the receptor’s intracellular surface, there are two peptide loops, the M1-M2 linker and the much larger M3-M4 linker that incorporates binding sites for receptor-associated molecules such as the synaptic scaffold protein, gephyrin, and also consensus sites for protein kinase phosphorylation (<xref ref-type="bibr" rid="bibr34-2398212819858249">Jacob et al., 2008</xref>; <xref ref-type="bibr" rid="bibr53-2398212819858249">Luscher et al., 2011</xref>; <xref ref-type="bibr" rid="bibr65-2398212819858249">Moss and Smart, 2001</xref>). These GABA receptors were clearly ionotropic in nature capable of enabling rapid flux of Cl<sup>–</sup> across the cell membrane.</p>
</sec>
<sec id="section6-2398212819858249">
<title>The GABA<sub>B</sub> receptor</title>
<p>Towards the end of the 1970s and early 1980s, Norman Bowery and colleagues were studying how GABA affected the release of noradrenaline in the heart and they identified another type of GABA receptor. This receptor was insensitive to the specific GABA receptor antagonist, bicuculline, and could be activated by the selective agonist, baclofen (<xref ref-type="bibr" rid="bibr9-2398212819858249">Bowery et al., 1980</xref>). These receptors were clearly different to the ionotropic GABA receptors, and they were classed as GABA<sub>B</sub> receptors (<xref ref-type="bibr" rid="bibr8-2398212819858249">Bowery, 1993</xref>) and assigned to the class C G-protein-coupled receptor (GPCR) superfamily in comparison to the ionotropic receptors that were designated as GABA<sub>A</sub> receptors.</p>
<p>We now know that the GABA<sub>B</sub> receptor once activated by GABA or other agonists, for example, baclofen, signals via opening inwardly rectifying K<sup>+</sup> channels, by closing voltage-gated Ca<sup>2+</sup> channels, and by modulating adenylate cyclase activity. To do so, it must assemble from two distinct subunits that were subsequently cloned (<xref ref-type="bibr" rid="bibr37-2398212819858249">Jones et al., 1998</xref>; <xref ref-type="bibr" rid="bibr39-2398212819858249">Kaupmann et al., 1997</xref>, <xref ref-type="bibr" rid="bibr40-2398212819858249">1998</xref>; <xref ref-type="bibr" rid="bibr97-2398212819858249">White et al., 1998</xref>). The R1 and R2 subunits co-assemble as an obligate heterodimer to ensure trafficking to the cell surface. The R1 subunit exists in several alternatively spliced versions, of which two major forms, R1a and R1b, are considered to be physiologically important and differ by the insertion of two Sushi domains in the <italic>N</italic>-terminal of the R1a subunit (<xref ref-type="bibr" rid="bibr6-2398212819858249">Bettler et al., 2004</xref>).</p>
<p>Similar to the structural and functional diversity displayed by GABA<sub>A/B</sub> receptors, heterogeneity of GABA transporters (GAT) is also evident (<xref ref-type="bibr" rid="bibr38-2398212819858249">Kanner and Bendahan, 1990</xref>). Molecular approaches have confirmed this diversity (<xref ref-type="bibr" rid="bibr7-2398212819858249">Borden et al., 1992</xref>; <xref ref-type="bibr" rid="bibr29-2398212819858249">Guastella et al., 1990</xref>), and GATs are designated to belong to a family of neurotransmitter–Na<sup>+</sup> symporters (<xref ref-type="bibr" rid="bibr81-2398212819858249">Scimemi, 2014</xref>). The function of GATs can be regulated by both post-translational modification (<xref ref-type="bibr" rid="bibr71-2398212819858249">Quick et al., 2004</xref>; <xref ref-type="bibr" rid="bibr98-2398212819858249">Whitworth and Quick, 2001</xref>) and selective ligands, such as nipecotic acid (<xref ref-type="bibr" rid="bibr42-2398212819858249">Krause and Schwarz, 2005</xref>). Although six transporters are known, it is GAT 1-3 that are prominent. GABA transporter Type 1 (GAT1) and 3 (GAT3) are the major transporters expressed in the brain, whereas GAT2 is expressed at lower levels (<xref ref-type="bibr" rid="bibr81-2398212819858249">Scimemi, 2014</xref>). There is also a vesicular GABA transporter (VGAT), which is also known as a vesicular inhibitory amino acid transporter (VIAAT) (<xref ref-type="bibr" rid="bibr18-2398212819858249">Dumoulin et al., 1999</xref>; <xref ref-type="bibr" rid="bibr77-2398212819858249">Sagne et al., 1997</xref>). Targeting of GATs is an alternative and valuable target for the manipulation of GABAergic neurotransmission for disorders in which dysfunction is apparent (e.g. epilepsy, see below).</p>
</sec>
<sec id="section7-2398212819858249">
<title>The 21st century and into the future</title>
<p>The discovery of a rich array of subunits available for assembly into GABA<sub>A</sub> receptors was unexpected, and raised many questions that we are still addressing today. These can be loosely grouped into the following categories:</p>
<list id="list2-2398212819858249" list-type="order">
<list-item>
<p>In terms of <italic>physiology and structure</italic> – Are there rules for subunit assembly? How many different receptor subtypes are there and what roles do they play? Are GABA receptors differentially expressed across the brain and even in single neurons? Why is there receptor heterogeneity? Such basic questions for which we have limited information.</p>
</list-item>
<list-item>
<p>With regard to <italic>pharmacology and therapeutics</italic> – Can drugs selectively modulate some GABA receptors but not others? Do we know where drugs bind on GABA receptors? Can these sites be exploited for future therapeutics?</p>
</list-item>
<list-item>
<p>And in terms of <italic>neurology and psychiatry</italic> – Do aberrant inhibition and dysfunctional GABA receptors underlie specific neurological/neuropsychiatric diseases?</p>
</list-item>
</list>
<p>Some answers to these questions are emerging. There are rules governing receptor subunit assembly since the number of subunits available would suggest in excess of 150,000 different GABA receptors are possible, and yet in the brain, this is likely to be highly restricted to around ~50 or so tentatively determined using subunit-selective antisera and functional expression experiments (<xref ref-type="bibr" rid="bibr67-2398212819858249">Olsen and Sieghart, 2009</xref>) (<xref ref-type="fig" rid="fig3-2398212819858249">Figure 3</xref>). Typically, many physiologically relevant GABA receptors are thought to be mainly composed of αβγ subunits usually in a stoichiometry of 2:2:1 with identical α and β subunit pairs; however, there is also evidence that α and β subunit pairs can differ in some receptors (e.g. α2 with α3) (<xref ref-type="bibr" rid="bibr17-2398212819858249">Duggan et al., 1991</xref>; <xref ref-type="bibr" rid="bibr57-2398212819858249">McKernan et al., 1991</xref>; <xref ref-type="bibr" rid="bibr56-2398212819858249">McKernan and Whiting, 1996</xref>). Thus, the precise subunit composition of many native GABA<sub>A</sub> receptors still needs to be verified.</p>
<fig id="fig3-2398212819858249" orientation="portrait" position="float">
<label>Figure 3.</label>
<caption>
<p>Subunit composition of native GABA<sub>A</sub> receptors.</p>
<p>The three lists are designed with minor modifications in terms of assignments from Table 3 in <xref ref-type="bibr" rid="bibr66-2398212819858249">Olsen and Sieghart (2008)</xref> showing the likeliest combinations of GABA<sub>A</sub> receptors subunits that are thought to exist in the mammalian brain. The probability of existence of a receptor in the brain is considered highest in the left panel and less so in the middle to right panels. x and y signify that different copies of α and β subunits may co-assemble in the same receptor pentamer.</p>
</caption>
<graphic xlink:href="10.1177_2398212819858249-fig3"></graphic>
</fig>
<p>The physiological roles that GABA<sub>A</sub> receptors play are multifarious. At early stages of development, there are roles in neurogenesis and synaptogenesis promoting neurodevelopment and neuronal excitation (<xref ref-type="bibr" rid="bibr4-2398212819858249">Ben Ari, 2002</xref>; <xref ref-type="bibr" rid="bibr5-2398212819858249">Ben Ari et al., 2007</xref>), although this has been challenged (<xref ref-type="bibr" rid="bibr11-2398212819858249">Bregestovski and Bernard, 2012</xref>; <xref ref-type="bibr" rid="bibr94-2398212819858249">Valeeva et al., 2016</xref>). However, their pre-eminent role is to provide neural inhibition to control network excitability (<xref ref-type="bibr" rid="bibr20-2398212819858249">Farrant and Kaila, 2007</xref>). This effect proceeds via GABA<sub>A</sub> receptors associated with two distinct membrane domains: inhibitory synapses, where rapid but brief, quantal release of GABA causes intense inhibition via activation of mostly αβγ subunit-containing receptors; and at extrasynaptic sites, where ambient low levels of GABA levels initiate tonic inhibition, via αβγ, αβδ and αβ containing receptors, which performs a less intense but more persistent inhibitory role (<xref ref-type="bibr" rid="bibr21-2398212819858249">Farrant and Nusser, 2005</xref>; <xref ref-type="bibr" rid="bibr62-2398212819858249">Mody, 2001</xref>). The effectiveness of inhibition depends upon the location of GABA synapses and the subunit composition of individual GABA<sub>A</sub> receptors, and crucially on the timing of activation with regard to concurrent excitation. All are critical aspects in determining the high-order level of neural network excitation.</p>
<p>The diversity of receptor subunits spawned many studies investigating the types of GABA<sub>A</sub> receptors expressed in neurons across the central nervous system. This has revealed distinct expression profiles for selected subunits (<xref ref-type="fig" rid="fig4-2398212819858249">Figure 4</xref>), such as for example, α6 in cerebellar granule cells, and α5 subunits predominant in the hippocampus and selected cortical areas. The differential expression patterns imply that there are physiological roles underlying GABA<sub>A</sub> receptor heterogeneity. This is supported by other studies showing that the subunit composition of the receptor can have profound effects on its functional profile, including the potency of GABA, the kinetics of receptor activation and desensitisation and the pharmacological phenotype (<xref ref-type="bibr" rid="bibr28-2398212819858249">Gingrich et al., 1995</xref>; <xref ref-type="bibr" rid="bibr41-2398212819858249">Korpi et al., 2002</xref>; <xref ref-type="bibr" rid="bibr49-2398212819858249">Lavoie et al., 1997</xref>; <xref ref-type="bibr" rid="bibr64-2398212819858249">Mortensen et al., 2011</xref>; <xref ref-type="bibr" rid="bibr69-2398212819858249">Picton and Fisher, 2007</xref>).</p>
<fig id="fig4-2398212819858249" orientation="portrait" position="float">
<label>Figure 4.</label>
<caption>
<p>Cellular expression profiles of GABA<sub>A</sub> receptors subunits.</p>
<p>The text boxes show the major sites of expression of GABA<sub>A</sub> receptor α subunits that are also depicted in diagrammatic form in the schematic parasagittal section through the brain. The relative sizes of the spheres indicate the extent of GABA<sub>A</sub> receptor α subunit expression. Data have been accrued from numerous immunofluorescence studies, and mostly taken as a collation from (<xref ref-type="bibr" rid="bibr27-2398212819858249">Fritschy and Brunig, 2003</xref>).</p>
</caption>
<graphic xlink:href="10.1177_2398212819858249-fig4"></graphic>
</fig>
<p>Recently, our understanding of the structure of GABA<sub>A</sub> receptors has undergone marked changes from our early perception of circular ‘doughnut-shaped’ entities, labelled with approximate positions of drug/modulator binding sites, to detailed structural homology models. These models were based on other receptors from the same superfamily whose atomic structures had been resolved. Later, high-resolution crystal structures of initially homomeric receptors and chimeric (bacterial homologue-GABA<sub>A</sub> receptor subunit) receptors (<xref ref-type="fig" rid="fig5-2398212819858249">Figure 5</xref>) became available, and now most recently, we have some atomic structures for heteromeric GABA<sub>A</sub> receptors that are expressed in the brain, composed of α, β and γ subunits with and without bound ligands. This rapid structural development initially relied on a structure for the β3 homomeric GABA receptor (<xref ref-type="bibr" rid="bibr60-2398212819858249">Miller and Aricescu, 2014</xref>), then GLIC-GABA<sub>A</sub>R α1 subunit chimera (<xref ref-type="bibr" rid="bibr48-2398212819858249">Laverty et al., 2017</xref>), revealing both the modular structure of the receptor and some important modulatory binding sites, for example, for the modulatory neurosteroids (<xref ref-type="bibr" rid="bibr48-2398212819858249">Laverty et al., 2017</xref>) reported simultaneously for a β3-α5 chimeric GABA receptor structure (<xref ref-type="bibr" rid="bibr61-2398212819858249">Miller et al., 2017</xref>). Together, these structures, and particularly the seminal cryo-electron microscopy (EM) structures of GABA<sub>A</sub> receptors that followed, revealed the ECD and associated GABA binding loops (A-F), the central anion-conducting pore region in the TMDs, and identified roles for several subdomains of the receptor in the process of receptor activation, including the channel activation gate, the deep lying desensitisation gate in the TMD, and the linker regions between the ECD and TMD (<xref ref-type="bibr" rid="bibr13-2398212819858249">Corringer et al., 2012</xref>; <xref ref-type="bibr" rid="bibr47-2398212819858249">Laverty et al., 2019</xref>; <xref ref-type="bibr" rid="bibr58-2398212819858249">Masiulis et al., 2019</xref>; <xref ref-type="bibr" rid="bibr68-2398212819858249">Phulera et al., 2018</xref>; <xref ref-type="bibr" rid="bibr89-2398212819858249">Smart and Paoletti, 2012</xref>; <xref ref-type="bibr" rid="bibr104-2398212819858249">Zhu et al., 2018</xref>). Despite this level of new knowledge, one area is notable by its absence from these structures and this concerns the intracellular domain (ICD) represented largely by the M3-M4 linker, the site of receptor phosphorylation and binding of receptor-associated molecules such as gephryin (<xref ref-type="bibr" rid="bibr53-2398212819858249">Luscher et al., 2011</xref>) and the GARHLs (<xref ref-type="bibr" rid="bibr99-2398212819858249">Yamasaki et al., 2017</xref>). This domain is invariably removed from receptor structures due to its perceived ability to hamper crystallisation and structural determination by cryo-EM, which may reflect difficulties in forming a stable structure. Thus, we have little or no understanding of the shape of the ICD, apart from what can be extrapolated from the <italic>Torpedo</italic> nicotinic acetylcholine receptor (<xref ref-type="bibr" rid="bibr93-2398212819858249">Unwin, 2005</xref>). It is possible that future development of cryo-EM methods will enable the resolution of this important area.</p>
<fig id="fig5-2398212819858249" orientation="portrait" position="float">
<label>Figure 5.</label>
<caption>
<p>Structures of the GABA<sub>A</sub> receptor: (a) Shows a chimeric GABA<sub>A</sub> receptor composed of an extracellular domain (orange) from GLIC and transmembrane domain from the GABA<sub>A</sub> receptor α1 subunit (green). Note GLIC is a homomer and allows the expression of a pentamer of α1 subunit TMDs. Schematic based on study by <xref ref-type="bibr" rid="bibr48-2398212819858249">Laverty et al., 2017</xref>. (b) Cryo-EM structure of an α1β3γ2L GABA<sub>A</sub> receptor in ribbon format. The α1 subunits are red, β3 subunits are green and the γ2L subunit is yellow; the nanobody used to isolate the receptor protein (blue). Note the resolution of the initial part of the ICD. Images are taken from the protein databank (PDB 6I53) (<xref ref-type="bibr" rid="bibr47-2398212819858249">Laverty et al., 2019</xref>).</p>
</caption>
<graphic xlink:href="10.1177_2398212819858249-fig5"></graphic>
</fig>
<p>For many years, there has been a concerted effort to determine how drugs affect the function of GABA<sub>A</sub> receptors and to deduce where they bind (<xref ref-type="bibr" rid="bibr41-2398212819858249">Korpi et al., 2002</xref>). The earliest example concerned the benzodiazepines since it was clear from the first cloning paper that GABA receptors composed of α and β subunits lacked high sensitivity to the benzodiazepines. Only the later incorporation of the γ subunit in the receptor resolved this conundrum. Despite this important observation, there are very few drugs that can be truly classed as GABA<sub>A</sub> receptor subtype specific. Many ligands may exhibit some preference for modulating specific GABA receptors, but at higher concentrations or doses, they frequently lose their selectivity. Achieving a high degree of receptor selectivity is an important goal, and worthy of pursuit for future therapeutic gain. This important concept has been realised by the creative use of mouse genetics to either remove (knock-out) or, more subtly, replace (knock-in) wild-type GABA receptor subunits with mutant counterparts that lack sensitivity to particular drugs. Generally, the knock-out approach is no longer favoured, given the propensity for adaptive compensatory changes and sometimes a severe phenotype that confounds interpretation. Using the knock-in approach, a seminal study targeted a key residue (histidine 101) in receptor α subunits, which was necessary for benzodiazepine action (<xref ref-type="bibr" rid="bibr76-2398212819858249">Rudolph et al., 1999</xref>), and demonstrated that their classic quadruple effects (anxiolysis, sedation, muscle relaxation and amnesia) are likely associated with neural circuits involving GABA<sub>A</sub> receptors composed of specific receptor subtypes. For example, removing benzodiazepine sensitivity from receptor α2 subunits resulted in reduced anxiolysis without affecting sedation by benzodiazepines (<xref ref-type="bibr" rid="bibr76-2398212819858249">Rudolph et al., 1999</xref>). Similarly, α5 subunits were associated with benzodiazepine-induced amnesia (<xref ref-type="bibr" rid="bibr74-2398212819858249">Rudolph and Mohler, 2004</xref>). These, among others, are sites that are being exploited for therapeutic purposes to provide anxiolytics that are non-sedative (α2, α3), and to provide cognitive enhancers that may be useful in some conditions of neurodegeneration (α5). Extending this approach to receptor β2 and β3 subunits and the activity of general anaesthetics revealed another important residue in the TMD that distinguishes between the modulation of GABA<sub>A</sub> receptors by various intravenous anaesthetics (<xref ref-type="bibr" rid="bibr73-2398212819858249">Rudolph and Antkowiak, 2004</xref>). Similar approaches have been adopted to establish that GABA receptors in the spinal cord play a significant role in pain processing and modulation of these receptors may offer possibilities for new analgesics (<xref ref-type="bibr" rid="bibr103-2398212819858249">Zeilhofer et al., 2009</xref>).</p>
<p>Defining the precise location of binding sites on high-resolution GABA receptor structures will provide an excellent opportunity for new drug design. To date, most ligand docking has been performed with general anaesthetic agents either making use of photoactive derivatives to covalently bind to the receptor (<xref ref-type="bibr" rid="bibr50-2398212819858249">Li et al., 2006</xref>) or solving crystal structures with anaesthetics bound in situ (<xref ref-type="bibr" rid="bibr100-2398212819858249">Yip et al., 2013</xref>). However, this is set to change with the advent of high-resolution GABA<sub>A</sub> receptor structures (<xref ref-type="bibr" rid="bibr48-2398212819858249">Laverty et al., 2017</xref>; <xref ref-type="bibr" rid="bibr58-2398212819858249">Masiulis et al., 2019</xref>).</p>
<p>The increased understanding of the cellular, molecular and structural properties of GABA<sub>A</sub> receptors has revealed the likelihood of their playing multiple roles in neurological and psychiatric diseases, in addition to identifying new potential drug targets in the receptor protein. Dysfunctional inhibition and GABA<sub>A</sub> receptors have been associated with, for example, anxiety, depression, epilepsy, autism, Angelman’s syndrome, Fragile-X syndrome, schizophrenia and Down syndrome (<xref ref-type="bibr" rid="bibr10-2398212819858249">Braat and Kooy, 2015</xref>; <xref ref-type="bibr" rid="bibr31-2398212819858249">Hines et al., 2012</xref>; <xref ref-type="bibr" rid="bibr55-2398212819858249">Macdonald et al., 2010</xref>; <xref ref-type="bibr" rid="bibr75-2398212819858249">Rudolph and Mohler, 2014</xref>; <xref ref-type="bibr" rid="bibr101-2398212819858249">Yuan et al., 2015</xref>). The involvement of GABA inhibitory systems invariably takes the form of gain-of-function or loss-of-function at the receptor level, but of course, the consequential network effects can be far more complex. For epilepsy, there is an increasing diversity of genetic mutations that associate with multiple clinical phenotypes directly correlating receptor dysfunction with disease (<xref ref-type="bibr" rid="bibr55-2398212819858249">Macdonald et al., 2010</xref>). While, for epilepsy, this often involves a loss-of-function, there are circumstances where a gain-of-function can be problematic such as in some forms of absence epilepsy, where no underlying mutations are apparent in the receptor protein, but tonic inhibition is increased due to aberrant GABA transport (<xref ref-type="bibr" rid="bibr12-2398212819858249">Cope et al., 2009</xref>).</p>
<p>Increased GABA inhibition is also apparent in Down syndrome and its reversal using either a GABA antagonist or α5 benzodiazepine inverse agonists appears to reverse the cognitive decline that is associated with the Down phenotype in animal models (<xref ref-type="bibr" rid="bibr22-2398212819858249">Fernandez et al., 2007</xref>). What has also become apparent with some neurodevelopmental disorders, such as schizophrenia, are changes that occur to receptor subunit levels, such as the δ and α5 subunits, that could lead to deficits in tonic, and for other subunits, synaptic inhibition. A similar outcome has also been noted associating depression with GABA inhibition, with GABAergic deficits (e.g. low GABA levels in the brain) thought to be one cause since these can be reversed by anti-depressant agents (<xref ref-type="bibr" rid="bibr75-2398212819858249">Rudolph and Mohler, 2014</xref>). Thus, the field of GABA therapeutics is expanding and becoming prominent and argues for increased development of subtype-selective agents to combat central nervous system diseases. It is also encouraging that relatively new unexplored sites for drug binding are being revealed, evident from the largely unstudied α<sup>+</sup>–β<sup>–</sup> interface, where novel drugs can exert modulatory actions on GABA<sub>A</sub> receptors (<xref ref-type="bibr" rid="bibr95-2398212819858249">Varagic et al., 2013</xref>) at a site that shares homology with the benzodiazepine binding site at the α<sup>+</sup>–γ<sup>–</sup> subunit interface.</p>
</sec>
<sec id="section8-2398212819858249">
<title>And so to the future</title>
<p>Manipulation of GABA inhibition in animal models and humans will become ever more sophisticated with the use of new subtype-selective drugs that target known binding sites as these become identified by new structural studies using crystallography and cryo-EM. To confer specificity, greater use of antibody fragments (variable domain of new antigen receptors (VNARs) and nanobodies) will enable the delivery of less specific drugs to particular receptor isoforms, especially where such binding sites are defined at receptor subunit interfaces.</p>
<p>Other methods to control inhibition will rely on interneuron manipulation driven by using optogenetics and chemogenetic approaches, supported by optical neurobiological methods coupled to photochemical probes targeting the GABA<sub>A</sub> receptor (<xref ref-type="bibr" rid="bibr51-2398212819858249">Lin et al., 2015</xref>; <xref ref-type="bibr" rid="bibr63-2398212819858249">Mortensen et al., 2014</xref>; <xref ref-type="bibr" rid="bibr102-2398212819858249">Yue et al., 2012</xref>). These latter agents will have in-built light-driven ‘molecular switches’ (e.g. azobenzenes) to flip molecular structure and functionality from neutral to active in terms of therapeutic effect in vivo. The challenge will lie in being able, in intact brain structures, to deliver light at the appropriate wavelength to the correct neural circuits. Nevertheless, the ability to dynamically manipulate inhibition will have significant impact on a range of neurological diseases and is a goal that is worthy of our aspiration.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="COI-statement">
<p><bold>Declaration of conflicting interests:</bold> The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure">
<p><bold>Funding:</bold> The author(s) received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barber</surname><given-names>RP</given-names></name><name><surname>Vaughn</surname><given-names>JE</given-names></name><name><surname>Saito</surname><given-names>K</given-names></name></person-group>, <etal>et al</etal> (<year>1978</year>) <article-title>GABAergic terminals are presynaptic to primary afferent terminals in the substantia gelatinosa of the rat spinal cord</article-title>. <source/>Brain Research
<volume>141</volume>(<issue>1</issue>): <fpage>35</fpage>–<lpage>55</lpage>.<pub-id pub-id-type="pmid">624076</pub-id></mixed-citation>
</ref>
<ref id="bibr2-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barnard</surname><given-names>EA</given-names></name><name><surname>Darlison</surname><given-names>MG</given-names></name><name><surname>Seeburg</surname><given-names>P</given-names></name></person-group> (<year>1987</year>) <article-title>Molecular biology of the GABA<sub>A</sub> receptor: The receptor/channel super-family</article-title>. <source/>Trends in Neurosciences
<volume>10</volume>(<issue>12</issue>): <fpage>502</fpage>–<lpage>509</lpage>.</mixed-citation>
</ref>
<ref id="bibr3-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Beaumont</surname><given-names>K</given-names></name><name><surname>Chilton</surname><given-names>WS</given-names></name><name><surname>Yamamura</surname><given-names>HI</given-names></name></person-group>, <etal>et al</etal> (<year>1978</year>) <article-title>Muscimol binding in rat brain: Association with synaptic GABA receptors</article-title>. <source/>Brain Research
<volume>148</volume>(<issue>1</issue>): <fpage>153</fpage>–<lpage>162</lpage>.<pub-id pub-id-type="pmid">207386</pub-id></mixed-citation>
</ref>
<ref id="bibr4-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ben Ari</surname><given-names>Y</given-names></name></person-group> (<year>2002</year>) <article-title>Excitatory actions of GABA during development: The nature of the nurture</article-title>. <source/>Nature Reviews: Neuroscience
<volume>3</volume>(<issue>9</issue>): <fpage>728</fpage>–<lpage>739</lpage>.<pub-id pub-id-type="pmid">12209121</pub-id></mixed-citation>
</ref>
<ref id="bibr5-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ben Ari</surname><given-names>Y</given-names></name><name><surname>Gaiarsa</surname><given-names>JL</given-names></name><name><surname>Tyzio</surname><given-names>R</given-names></name></person-group>, <etal>et al</etal> (<year>2007</year>) <article-title>GABA: A pioneer transmitter that excites immature neurons and generates primitive oscillations</article-title>. <source/>Physiological Reviews
<volume>87</volume>(<issue>4</issue>): <fpage>1215</fpage>–<lpage>1284</lpage>.<pub-id pub-id-type="pmid">17928584</pub-id></mixed-citation>
</ref>
<ref id="bibr6-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bettler</surname><given-names>B</given-names></name><name><surname>Kaupmann</surname><given-names>K</given-names></name><name><surname>Mosbacher</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal> (<year>2004</year>) <article-title>Molecular structure and physiological functions of GABA<sub>B</sub> receptors</article-title>. <source/>Physiological Reviews
<volume>84</volume>(<issue>3</issue>): <fpage>835</fpage>–<lpage>867</lpage>.<pub-id pub-id-type="pmid">15269338</pub-id></mixed-citation>
</ref>
<ref id="bibr7-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Borden</surname><given-names>LA</given-names></name><name><surname>Smith</surname><given-names>KE</given-names></name><name><surname>Hartig</surname><given-names>PR</given-names></name></person-group>, <etal>et al</etal> (<year>1992</year>) <article-title>Molecular heterogeneity of the gamma-aminobutyric acid (GABA) transport system: Cloning of two novel high affinity GABA transporters from rat brain</article-title>. <source/>The Journal of Biological Chemistry
<volume>267</volume>(<issue>29</issue>): <fpage>21098</fpage>–<lpage>21104</lpage>.<pub-id pub-id-type="pmid">1400419</pub-id></mixed-citation>
</ref>
<ref id="bibr8-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bowery</surname><given-names>NG</given-names></name></person-group> (<year>1993</year>) <article-title>GABA<sub>B</sub> receptor pharmacology</article-title>. <source/>Annual Review of Pharmacology and Toxicology
<volume>33</volume>: <fpage>109</fpage>–<lpage>147</lpage>.</mixed-citation>
</ref>
<ref id="bibr9-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bowery</surname><given-names>NG</given-names></name><name><surname>Hill</surname><given-names>DR</given-names></name><name><surname>Hudson</surname><given-names>AL</given-names></name></person-group>, <etal>et al</etal> (<year>1980</year>) <article-title>(-)Baclofen decreases neurotransmitter release in the mammalian CNS by an action at a novel GABA receptor</article-title>. <source/>Nature
<volume>283</volume>(<issue>5742</issue>): <fpage>92</fpage>–<lpage>94</lpage>.<pub-id pub-id-type="pmid">6243177</pub-id></mixed-citation>
</ref>
<ref id="bibr10-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Braat</surname><given-names>S</given-names></name><name><surname>Kooy</surname><given-names>R</given-names></name></person-group> (<year>2015</year>) <article-title>The GABA<sub>A</sub> receptor as a therapeutic target for neurodevelopmental disorders</article-title>. <source/>Neuron
<volume>86</volume>(<issue>5</issue>): <fpage>1119</fpage>–<lpage>1130</lpage>.<pub-id pub-id-type="pmid">26050032</pub-id></mixed-citation>
</ref>
<ref id="bibr11-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bregestovski</surname><given-names>P</given-names></name><name><surname>Bernard</surname><given-names>C</given-names></name></person-group> (<year>2012</year>) <article-title>Excitatory GABA: How a correct observation</article-title>
<month>5</month>
<article-title>turn out to be an experimental artifact</article-title>. <source/>Frontiers in Pharmacology
<volume>3</volume>: <fpage>65</fpage>. doi.org/10.3389/fphar.2012.00065</mixed-citation>
</ref>
<ref id="bibr12-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cope</surname><given-names>DW</given-names></name><name><surname>Di Giovanni</surname><given-names>G</given-names></name><name><surname>Fyson</surname><given-names>SJ</given-names></name></person-group>, <etal>et al</etal> (<year>2009</year>) <article-title>Enhanced tonic GABA<sub>A</sub> inhibition in typical absence epilepsy</article-title>. <source/>Nature Medicine
<volume>15</volume>(<issue>12</issue>): <fpage>1392</fpage>–<lpage>1398</lpage>.</mixed-citation>
</ref>
<ref id="bibr13-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Corringer</surname><given-names>PJ</given-names></name><name><surname>Poitevin</surname><given-names>F</given-names></name><name><surname>Prevost</surname><given-names>MS</given-names></name></person-group>, <etal>et al</etal> (<year>2012</year>) <article-title>Structure and pharmacology of pentameric receptor channels: From bacteria to brain</article-title>. <source/>Structure
<volume>20</volume>(<issue>6</issue>): <fpage>941</fpage>–<lpage>956</lpage>.<pub-id pub-id-type="pmid">22681900</pub-id></mixed-citation>
</ref>
<ref id="bibr14-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Curtis</surname><given-names>DR</given-names></name><name><surname>Duggan</surname><given-names>AW</given-names></name><name><surname>Felix</surname><given-names>D</given-names></name></person-group>, <etal>et al</etal> (<year>1970</year>) <article-title>GABA, bicuculline and central inhibition</article-title>. <source/>Nature
<volume>226</volume>(<issue>5252</issue>): <fpage>1222</fpage>–<lpage>1224</lpage>.<pub-id pub-id-type="pmid">4393081</pub-id></mixed-citation>
</ref>
<ref id="bibr15-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Curtis</surname><given-names>DR</given-names></name><name><surname>Phillis</surname><given-names>JW</given-names></name><name><surname>Watkins</surname><given-names>JC</given-names></name></person-group> (<year>1959</year>) <article-title>The depression of spinal neurones by gamma-amino-n-butyric acid and beta-alanine</article-title>. <source/>The Journal of Physiology
<volume>146</volume>(<issue>1</issue>): <fpage>185</fpage>–<lpage>203</lpage>.<pub-id pub-id-type="pmid">13655226</pub-id></mixed-citation>
</ref>
<ref id="bibr16-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dreifuss</surname><given-names>JJ</given-names></name><name><surname>Kelly</surname><given-names>JS</given-names></name><name><surname>Krnjevic</surname><given-names>K</given-names></name></person-group> (<year>1969</year>) <article-title>Cortical inhibition and gamma-aminobutyric acid</article-title>. <source/>Experimental Brain Research
<volume>9</volume>(<issue>2</issue>): <fpage>137</fpage>–<lpage>154</lpage>.<pub-id pub-id-type="pmid">5346460</pub-id></mixed-citation>
</ref>
<ref id="bibr17-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Duggan</surname><given-names>MJ</given-names></name><name><surname>Pollard</surname><given-names>S</given-names></name><name><surname>Stephenson</surname><given-names>FA</given-names></name></person-group> (<year>1991</year>) <article-title>Immunoaffinity purification of GABA<sub>A</sub> receptor α-subunit iso-oligomers: Demonstration of receptor populations containing α1 α2, α1 α3, and α2 α3 subunit pairs</article-title>. <source/>The Journal of Biological Chemistry
<volume>266</volume>(<issue>36</issue>): <fpage>24778</fpage>–<lpage>24784</lpage>.<pub-id pub-id-type="pmid">1662216</pub-id></mixed-citation>
</ref>
<ref id="bibr18-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dumoulin</surname><given-names>A</given-names></name><name><surname>Rostaing</surname><given-names>P</given-names></name><name><surname>Bedet</surname><given-names>C</given-names></name></person-group>, <etal>et al</etal> (<year>1999</year>) <article-title>Presence of the vesicular inhibitory amino acid transporter in GABAergic and glycinergic synaptic terminal boutons</article-title>. <source/>Journal of Cell Science
<volume>112</volume>(<issue>pt. 6</issue>): <fpage>811</fpage>–<lpage>823</lpage>.<pub-id pub-id-type="pmid">10036231</pub-id></mixed-citation>
</ref>
<ref id="bibr19-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ernst</surname><given-names>M</given-names></name><name><surname>Bruckner</surname><given-names>S</given-names></name><name><surname>Boresch</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal> (<year>2005</year>) <article-title>Comparative models of GABA<sub>A</sub> receptor extracellular and trans-membrane domains: Important insights in pharmacology and function</article-title>. <source/>Molecular Pharmacology
<volume>68</volume>(<issue>5</issue>): <fpage>1291</fpage>–<lpage>1300</lpage>.<pub-id pub-id-type="pmid">16103045</pub-id></mixed-citation>
</ref>
<ref id="bibr20-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Farrant</surname><given-names>M</given-names></name><name><surname>Kaila</surname><given-names>K</given-names></name></person-group> (<year>2007</year>) <article-title>The cellular, molecular and ionic basis of GABA<sub>A</sub> receptor signalling</article-title>. <source/>Progress in Brain Research
<volume>160</volume>: <fpage>59</fpage>–<lpage>87</lpage>.<pub-id pub-id-type="pmid">17499109</pub-id></mixed-citation>
</ref>
<ref id="bibr21-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Farrant</surname><given-names>M</given-names></name><name><surname>Nusser</surname><given-names>Z</given-names></name></person-group> (<year>2005</year>) <article-title>Variations on an inhibitory theme: Phasic and tonic activation of GABA<sub>A</sub> receptors</article-title>. <source/>Nature Reviews: Neuroscience
<volume>6</volume>(<issue>3</issue>): <fpage>215</fpage>–<lpage>229</lpage>.<pub-id pub-id-type="pmid">15738957</pub-id></mixed-citation>
</ref>
<ref id="bibr22-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fernandez</surname><given-names>F</given-names></name><name><surname>Morishita</surname><given-names>W</given-names></name><name><surname>Zuniga</surname><given-names>E</given-names></name></person-group>, <etal>et al</etal> (<year>2007</year>) <article-title>Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome</article-title>. <source/>Nature Neuroscience
<volume>10</volume>(<issue>4</issue>): <fpage>411</fpage>–<lpage>413</lpage>.<pub-id pub-id-type="pmid">17322876</pub-id></mixed-citation>
</ref>
<ref id="bibr23-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Florey</surname><given-names>E</given-names></name></person-group> (<year>1954</year>) <article-title>An inhibitory and an excitatory factor of mammalian central nervous system, and their action of a single sensory neuron</article-title>. <source/>Archives Internationales de Physiologie
<volume>62</volume>(<issue>1</issue>): <fpage>33</fpage>–<lpage>53</lpage>.<pub-id pub-id-type="pmid">13149232</pub-id></mixed-citation>
</ref>
<ref id="bibr24-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Florey</surname><given-names>E</given-names></name></person-group> (<year>1991</year>) <article-title>GABA: History and perspectives</article-title>. <source/>Canadian Journal of Physiology and Pharmacology
<volume>69</volume>(<issue>7</issue>): <fpage>1049</fpage>–<lpage>1056</lpage>.<pub-id pub-id-type="pmid">1954562</pub-id></mixed-citation>
</ref>
<ref id="bibr25-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Florey</surname><given-names>E</given-names></name><name><surname>McLennan</surname><given-names>H</given-names></name></person-group> (<year>1959</year>) <article-title>The effects of factor I and of gamma-aminobutyric acid on smooth muscle preparations</article-title>. <source/>The Journal of Physiology
<volume>145</volume>(<issue>1</issue>): <fpage>66</fpage>–<lpage>76</lpage>.<pub-id pub-id-type="pmid">13621421</pub-id></mixed-citation>
</ref>
<ref id="bibr26-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Franks</surname><given-names>NP</given-names></name></person-group> (<year>2015</year>) <article-title>Structural comparisons of ligand-gated ion channels in open, closed, and desensitized states identify a novel propofol-binding site on mammalian gamma-aminobutyric acid type A receptors</article-title>. <source/>Anesthesiology
<volume>122</volume>(<issue>4</issue>): <fpage>787</fpage>–<lpage>794</lpage>.<pub-id pub-id-type="pmid">25575161</pub-id></mixed-citation>
</ref>
<ref id="bibr27-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fritschy</surname><given-names>JM</given-names></name><name><surname>Brunig</surname><given-names>I</given-names></name></person-group> (<year>2003</year>) <article-title>Formation and plasticity of GABAergic synapses: Physiological mechanisms and pathophysiological implications</article-title>. <source/>Pharmacology &amp; Therapeutics
<volume>98</volume>(<issue>3</issue>): <fpage>299</fpage>–<lpage>323</lpage>.<pub-id pub-id-type="pmid">12782242</pub-id></mixed-citation>
</ref>
<ref id="bibr28-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gingrich</surname><given-names>KJ</given-names></name><name><surname>Roberts</surname><given-names>WA</given-names></name><name><surname>Kass</surname><given-names>RS</given-names></name></person-group> (<year>1995</year>) <article-title>Dependence of the GABA<sub>A</sub> receptor gating kinetics on the α-subunit isoform: Implications for structure-function relations and synaptic transmission</article-title>. <source/>The Journal of Physiology
<volume>489</volume>(<issue>Pt. 2</issue>): <fpage>529</fpage>–<lpage>543</lpage>.<pub-id pub-id-type="pmid">8847645</pub-id></mixed-citation>
</ref>
<ref id="bibr29-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guastella</surname><given-names>J</given-names></name><name><surname>Nelson</surname><given-names>N</given-names></name><name><surname>Nelson</surname><given-names>H</given-names></name></person-group>, <etal>et al</etal> (<year>1990</year>) <article-title>Cloning and expression of a rat brain GABA transporter</article-title>. <source/>Science
<volume>249</volume>(<issue>4974</issue>): <fpage>1303</fpage>–<lpage>1306</lpage>.<pub-id pub-id-type="pmid">1975955</pub-id></mixed-citation>
</ref>
<ref id="bibr30-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Haefely</surname><given-names>W</given-names></name><name><surname>Kulcsar</surname><given-names>A</given-names></name><name><surname>Mohler</surname><given-names>H</given-names></name></person-group>, <etal>et al</etal> (<year>1975</year>) <article-title>Possible involvement of GABA in the central actions of benzodiazepines</article-title>. <source/>Advances in Biochemical Psychopharmacology
<volume>14</volume>: <fpage>131</fpage>–<lpage>151</lpage>.</mixed-citation>
</ref>
<ref id="bibr31-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hines</surname><given-names>RM</given-names></name><name><surname>Davies</surname><given-names>PA</given-names></name><name><surname>Moss</surname><given-names>SJ</given-names></name></person-group>, <etal>et al</etal> (<year>2012</year>) <article-title>Functional regulation of GABA<sub>A</sub> receptors in nervous system pathologies</article-title>. <source/>Current Opinion in Neurobiology
<volume>22</volume>(<issue>3</issue>): <fpage>552</fpage>–<lpage>558</lpage>.<pub-id pub-id-type="pmid">22036769</pub-id></mixed-citation>
</ref>
<ref id="bibr32-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hosie</surname><given-names>AM</given-names></name><name><surname>Wilkins</surname><given-names>ME</given-names></name><name><surname>da Silva</surname><given-names>HMA</given-names></name></person-group>, <etal>et al</etal> (<year>2006</year>) <article-title>Endogenous neurosteroids regulate GABA<sub>A</sub> receptors through two discrete transmembrane sites</article-title>. <source/>Nature
<volume>444</volume>(<issue>7118</issue>): <fpage>486</fpage>–<lpage>489</lpage>.<pub-id pub-id-type="pmid">17108970</pub-id></mixed-citation>
</ref>
<ref id="bibr33-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Iversen</surname><given-names>LL</given-names></name><name><surname>Neal</surname><given-names>MJ</given-names></name></person-group> (<year>1968</year>) <article-title>The uptake of [<sup>3</sup>H]GABA by slices of rat cerebral cortex</article-title>. <source/>Journal of Neurochemistry
<volume>15</volume>(<issue>10</issue>): <fpage>1141</fpage>–<lpage>1149</lpage>.<pub-id pub-id-type="pmid">5711127</pub-id></mixed-citation>
</ref>
<ref id="bibr34-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jacob</surname><given-names>TC</given-names></name><name><surname>Moss</surname><given-names>SJ</given-names></name><name><surname>Jurd</surname><given-names>R</given-names></name></person-group> (<year>2008</year>) <article-title>GABA<sub>A</sub> receptor trafficking and its role in the dynamic modulation of neuronal inhibition</article-title>. <source/>Nature Reviews: Neuroscience
<volume>9</volume>(<issue>5</issue>): <fpage>331</fpage>–<lpage>343</lpage>.<pub-id pub-id-type="pmid">18382465</pub-id></mixed-citation>
</ref>
<ref id="bibr35-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jayakar</surname><given-names>SS</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Savechenkov</surname><given-names>PY</given-names></name></person-group>, <etal>et al</etal> (<year>2015</year>) <article-title>Positive and negative allosteric modulation of an α1β3γ2 γ-Aminobutyric Acid Type A (GABA<sub>A</sub>) Receptor by Binding to a Site in the Transmembrane Domain at the γ+-β- Interface</article-title>. <source/>The Journal of Biological Chemistry
<volume>290</volume>(<issue>38</issue>): <fpage>23432</fpage>–<lpage>23446</lpage>.<pub-id pub-id-type="pmid">26229099</pub-id></mixed-citation>
</ref>
<ref id="bibr36-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Johnston</surname><given-names>GA</given-names></name></person-group> (<year>2013</year>) <article-title>Advantages of an antagonist: Bicuculline and other GABA antagonists</article-title>. <source/>British Journal of Pharmacology
<volume>169</volume>(<issue>2</issue>): <fpage>328</fpage>–<lpage>336</lpage>.<pub-id pub-id-type="pmid">23425285</pub-id></mixed-citation>
</ref>
<ref id="bibr37-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jones</surname><given-names>KA</given-names></name><name><surname>Borowsky</surname><given-names>B</given-names></name><name><surname>Tamm</surname><given-names>JA</given-names></name></person-group>, <etal>et al</etal> (<year>1998</year>) <article-title>GABA<sub>B</sub> receptors function as a heteromeric assembly of the subunits GABA<sub>B</sub>R1 and GABA<sub>B</sub>R2</article-title>. <source/>Nature
<volume>396</volume>(<issue>6712</issue>): <fpage>674</fpage>–<lpage>679</lpage>.<pub-id pub-id-type="pmid">9872315</pub-id></mixed-citation>
</ref>
<ref id="bibr38-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kanner</surname><given-names>BI</given-names></name><name><surname>Bendahan</surname><given-names>A</given-names></name></person-group> (<year>1990</year>) <article-title>Two pharmacologically distinct sodium- and chloride-coupled high-affinity gamma-aminobutyric acid transporters are present in plasma membrane vesicles and reconstituted preparations from rat brain</article-title>. <source/>Proceedings of the National Academy of Sciences of the United States of America
<volume>87</volume>(<issue>7</issue>): <fpage>2550</fpage>–<lpage>2554</lpage>.<pub-id pub-id-type="pmid">2108440</pub-id></mixed-citation>
</ref>
<ref id="bibr39-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kaupmann</surname><given-names>K</given-names></name><name><surname>Huggel</surname><given-names>K</given-names></name><name><surname>Heid</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal> (<year>1997</year>) <article-title>Expression cloning of GABA<sub>B</sub> receptors uncovers similarity to metabotropic glutamate receptors</article-title>. <source/>Nature
<volume>386</volume>(<issue>6622</issue>): <fpage>239</fpage>–<lpage>246</lpage>.<pub-id pub-id-type="pmid">9069281</pub-id></mixed-citation>
</ref>
<ref id="bibr40-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kaupmann</surname><given-names>K</given-names></name><name><surname>Malitschek</surname><given-names>B</given-names></name><name><surname>Schuler</surname><given-names>V</given-names></name></person-group>, <etal>et al</etal> (<year>1998</year>) <article-title>GABA<sub>B</sub>-receptor subtypes assemble into functional heteromeric complexes</article-title>. <source/>Nature
<volume>396</volume>(<issue>6712</issue>): <fpage>683</fpage>–<lpage>687</lpage>.<pub-id pub-id-type="pmid">9872317</pub-id></mixed-citation>
</ref>
<ref id="bibr41-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Korpi</surname><given-names>ER</given-names></name><name><surname>Grunder</surname><given-names>G</given-names></name><name><surname>Luddens</surname><given-names>H</given-names></name></person-group> (<year>2002</year>) <article-title>Drug interactions at GABA<sub>A</sub> receptors</article-title>. <source/>Progress in Neurobiology
<volume>67</volume>(<issue>2</issue>): <fpage>113</fpage>–<lpage>159</lpage>.<pub-id pub-id-type="pmid">12126658</pub-id></mixed-citation>
</ref>
<ref id="bibr42-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Krause</surname><given-names>S</given-names></name><name><surname>Schwarz</surname><given-names>W</given-names></name></person-group> (<year>2005</year>) <article-title>Identification and selective inhibition of the channel mode of the neuronal GABA transporter 1</article-title>. <source/>Molecular Pharmacology
<volume>68</volume>(<issue>6</issue>): <fpage>1728</fpage>–<lpage>1735</lpage>.<pub-id pub-id-type="pmid">16150932</pub-id></mixed-citation>
</ref>
<ref id="bibr43-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Krnjevic</surname><given-names>K</given-names></name></person-group> (<year>2010</year>) <article-title>When and why amino acids?</article-title>
<source/>The Journal of Physiology
<volume>588</volume>(<issue>Pt. 1</issue>): <fpage>33</fpage>–<lpage>44</lpage>.<pub-id pub-id-type="pmid">19822549</pub-id></mixed-citation>
</ref>
<ref id="bibr44-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Krnjevic</surname><given-names>K</given-names></name><name><surname>Phillis</surname><given-names>JW</given-names></name></person-group> (<year>1963</year>) <article-title>Iontophoretic studies of neurones in the mammalian cerebral cortex</article-title>. <source/>The Journal of Physiology
<volume>165</volume>(<issue>2</issue>): <fpage>274</fpage>–<lpage>304</lpage>.<pub-id pub-id-type="pmid">14035891</pub-id></mixed-citation>
</ref>
<ref id="bibr45-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Krnjevic</surname><given-names>K</given-names></name><name><surname>Schwartz</surname><given-names>S</given-names></name></person-group> (<year>1967</year>) <article-title>The action of gamma-aminobutyric acid on cortical neurones</article-title>. <source/>Experimental Brain Research
<volume>3</volume>(<issue>4</issue>): <fpage>320</fpage>–<lpage>336</lpage>.<pub-id pub-id-type="pmid">6031164</pub-id></mixed-citation>
</ref>
<ref id="bibr46-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kuffler</surname><given-names>SW</given-names></name></person-group> (<year>1954</year>) <article-title>Mechanisms of activation and motor control of stretch receptors in lobster and crayfish</article-title>. <source/>Journal of Neurophysiology
<volume>17</volume>(<issue>6</issue>): <fpage>558</fpage>–<lpage>574</lpage>.<pub-id pub-id-type="pmid">13212426</pub-id></mixed-citation>
</ref>
<ref id="bibr47-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Laverty</surname><given-names>D</given-names></name><name><surname>Desai</surname><given-names>R</given-names></name><name><surname>Uchariski</surname><given-names>T</given-names></name></person-group>, <etal>et al</etal> (<year>2019</year>) <article-title>Cryo-EM structure of the human α1β3γ2 GABA<sub>A</sub> receptor in a lipid bilayer</article-title>. <source/>Nature
<volume>565</volume>(<issue>7740</issue>): <fpage>516</fpage>–<lpage>522</lpage>.<pub-id pub-id-type="pmid">30602789</pub-id></mixed-citation>
</ref>
<ref id="bibr48-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Laverty</surname><given-names>D</given-names></name><name><surname>Thomas</surname><given-names>P</given-names></name><name><surname>Field</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal> (<year>2017</year>) <article-title>Crystal structures of a GABA<sub>A</sub>-receptor chimera reveal new endogenous neurosteroid-binding sites</article-title>. <source/>Nature Structural and Molecular Biology
<volume>24</volume>(<issue>11</issue>): <fpage>977</fpage>–<lpage>985</lpage>.</mixed-citation>
</ref>
<ref id="bibr49-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lavoie</surname><given-names>AM</given-names></name><name><surname>Tingey</surname><given-names>JJ</given-names></name><name><surname>Harrison</surname><given-names>NL</given-names></name></person-group>, <etal>et al</etal> (<year>1997</year>) <article-title>Activation and deactivation rates of recombinant GABA<sub>A</sub> receptor channels are dependent on alpha-subunit isoform</article-title>. <source/>Biophysical Journal
<volume>73</volume>(<issue>5</issue>): <fpage>2518</fpage>–<lpage>2526</lpage>.<pub-id pub-id-type="pmid">9370445</pub-id></mixed-citation>
</ref>
<ref id="bibr50-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>GD</given-names></name><name><surname>Chiara</surname><given-names>DC</given-names></name><name><surname>Sawyer</surname><given-names>GW</given-names></name></person-group>, <etal>et al</etal> (<year>2006</year>) <article-title>Identification of a GABA<sub>A</sub> receptor anesthetic binding site at subunit interfaces by photolabeling with an etomidate analog</article-title>. <source/>The Journal of Neuroscience
<volume>26</volume>(<issue>45</issue>): <fpage>11599</fpage>–<lpage>11605</lpage>.<pub-id pub-id-type="pmid">17093081</pub-id></mixed-citation>
</ref>
<ref id="bibr51-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lin</surname><given-names>WC</given-names></name><name><surname>Tsai</surname><given-names>MC</given-names></name><name><surname>Davenport</surname><given-names>C</given-names></name></person-group>, <etal>et al</etal> (<year>2015</year>) <article-title>A comprehensive optogenetic pharmacology toolkit for in vivo control of GABA<sub>A</sub> receptors and synaptic inhibition</article-title>. <source/>Neuron
<volume>88</volume>(<issue>5</issue>): <fpage>879</fpage>–<lpage>891</lpage>.<pub-id pub-id-type="pmid">26606997</pub-id></mixed-citation>
</ref>
<ref id="bibr52-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lummis</surname><given-names>SC</given-names></name></person-group> (<year>2009</year>) <article-title>Locating GABA in GABA receptor binding sites</article-title>. <source/>Biochemical Society Transactions
<volume>37</volume>(<issue>Pt. 6</issue>): <fpage>1343</fpage>–<lpage>1346</lpage>.<pub-id pub-id-type="pmid">19909273</pub-id></mixed-citation>
</ref>
<ref id="bibr53-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Luscher</surname><given-names>B</given-names></name><name><surname>Fuchs</surname><given-names>T</given-names></name><name><surname>Kilpatrick</surname><given-names>C</given-names></name></person-group> (<year>2011</year>) <article-title>GABA<sub>A</sub> receptor trafficking-mediated plasticity of inhibitory synapses</article-title>. <source/>Neuron
<volume>70</volume>(<issue>3</issue>): <fpage>385</fpage>–<lpage>409</lpage>.<pub-id pub-id-type="pmid">21555068</pub-id></mixed-citation>
</ref>
<ref id="bibr54-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>MacDonald</surname><given-names>RL</given-names></name><name><surname>Olsen</surname><given-names>RW</given-names></name></person-group> (<year>1994</year>) <article-title>GABA<sub>A</sub> receptor channels</article-title>. <source/>Annual Review of Neuroscience
<volume>17</volume>: <fpage>569</fpage>–<lpage>602</lpage>.</mixed-citation>
</ref>
<ref id="bibr55-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Macdonald</surname><given-names>RL</given-names></name><name><surname>Kang</surname><given-names>JQ</given-names></name><name><surname>Gallagher</surname><given-names>MJ</given-names></name></person-group> (<year>2010</year>) <article-title>Mutations in GABA<sub>A</sub> receptor subunits associated with genetic epilepsies</article-title>. <source/>The Journal of Physiology
<volume>588</volume>(<issue>Pt. 11</issue>): <fpage>1861</fpage>–<lpage>1869</lpage>.<pub-id pub-id-type="pmid">20308251</pub-id></mixed-citation>
</ref>
<ref id="bibr56-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McKernan</surname><given-names>RM</given-names></name><name><surname>Whiting</surname><given-names>PJ</given-names></name></person-group> (<year>1996</year>) <article-title>Which GABA<sub>A</sub>-receptor subtypes really occur in the brain?</article-title>
<source/>Trends in Neurosciences
<volume>19</volume>(<issue>4</issue>): <fpage>139</fpage>–<lpage>143</lpage>.<pub-id pub-id-type="pmid">8658597</pub-id></mixed-citation>
</ref>
<ref id="bibr57-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McKernan</surname><given-names>RM</given-names></name><name><surname>Quirk</surname><given-names>K</given-names></name><name><surname>Prince</surname><given-names>R</given-names></name></person-group>, <etal>et al</etal> (<year>1991</year>) <article-title>GABA<sub>A</sub> receptor subtypes immunopurified from rat brain with alpha subunit-specific antibodies have unique pharmacological properties</article-title>. <source/>Neuron
<volume>7</volume>(<issue>4</issue>): <fpage>667</fpage>–<lpage>676</lpage>.<pub-id pub-id-type="pmid">1657058</pub-id></mixed-citation>
</ref>
<ref id="bibr58-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Masiulis</surname><given-names>S</given-names></name><name><surname>Desai</surname><given-names>R</given-names></name><name><surname>Uchariski</surname><given-names>T</given-names></name></person-group>, <etal>et al</etal> (<year>2019</year>) <article-title>GABA<sub>A</sub> receptor signalling mechanisms revealed by structural pharmacology</article-title>. <source/>Nature
<volume>565</volume>(<issue>7740</issue>): <fpage>454</fpage>–<lpage>461</lpage>.<pub-id pub-id-type="pmid">30602790</pub-id></mixed-citation>
</ref>
<ref id="bibr59-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miledi</surname><given-names>R</given-names></name><name><surname>Parker</surname><given-names>I</given-names></name><name><surname>Sumikawa</surname><given-names>K</given-names></name></person-group> (<year>1983</year>) <article-title>Recording of single gamma-aminobutyrate- and acetylcholine-activated receptor channels translated by exogenous mRNA in Xenopus Oocytes</article-title>. <source/>Proceedings of the Royal Society of London: Series B, Biological Sciences
<volume>218</volume>(<issue>1213</issue>): <fpage>481</fpage>–<lpage>484</lpage>.</mixed-citation>
</ref>
<ref id="bibr60-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miller</surname><given-names>PS</given-names></name><name><surname>Aricescu</surname><given-names>AR</given-names></name></person-group> (<year>2014</year>) <article-title>Crystal structure of a human GABA<sub>A</sub> receptor</article-title>. <source/>Nature
<volume>512</volume>(<issue>7514</issue>): <fpage>270</fpage>–<lpage>275</lpage>.<pub-id pub-id-type="pmid">24909990</pub-id></mixed-citation>
</ref>
<ref id="bibr61-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miller</surname><given-names>PS</given-names></name><name><surname>Scott</surname><given-names>S</given-names></name><name><surname>Masiulis</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal> (<year>2017</year>) <article-title>Structural basis for GABA<sub>A</sub> receptor potentiation by neurosteroids</article-title>. <source/>Nature Structural and Molecular Biology
<volume>24</volume>(<issue>11</issue>): <fpage>986</fpage>–<lpage>992</lpage>.</mixed-citation>
</ref>
<ref id="bibr62-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mody</surname><given-names>I</given-names></name></person-group> (<year>2001</year>) <article-title>Distinguishing between GABA<sub>A</sub> receptors responsible for tonic and phasic conductances</article-title>. <source/>Neurochemical Research
<volume>26</volume>(<issue>8–9</issue>): <fpage>907</fpage>–<lpage>913</lpage>.<pub-id pub-id-type="pmid">11699942</pub-id></mixed-citation>
</ref>
<ref id="bibr63-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mortensen</surname><given-names>M</given-names></name><name><surname>Iqbal</surname><given-names>F</given-names></name><name><surname>Pandurangan</surname><given-names>AP</given-names></name></person-group>, <etal>et al</etal> (<year>2014</year>) <article-title>Photo-antagonism of the GABA<sub>A</sub> receptor</article-title>. <source/>Nature Communications
<volume>5</volume>: <fpage>4454</fpage>. doi:<pub-id pub-id-type="doi">10.1038/ncomms5454</pub-id></mixed-citation>
</ref>
<ref id="bibr64-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mortensen</surname><given-names>M</given-names></name><name><surname>Patel</surname><given-names>B</given-names></name><name><surname>Smart</surname><given-names>TG</given-names></name></person-group> (<year>2011</year>) <article-title>GABA potency at GABA<sub>A</sub> receptors found in synaptic and extrasynaptic zones</article-title>. <source/>Frontiers in Cellular Neuroscience
<volume>6</volume>: <fpage>1</fpage>–<lpage>10</lpage>. doi: <pub-id pub-id-type="doi">10.3389/fncel.2012.00001</pub-id><pub-id pub-id-type="pmid">22319471</pub-id></mixed-citation>
</ref>
<ref id="bibr65-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Moss</surname><given-names>SJ</given-names></name><name><surname>Smart</surname><given-names>TG</given-names></name></person-group> (<year>2001</year>) <article-title>Constructing inhibitory synapses</article-title>. <source/>Nature Reviews Neuroscience
<volume>2</volume>(<issue>4</issue>): <fpage>240</fpage>–<lpage>250</lpage>.<pub-id pub-id-type="pmid">11283747</pub-id></mixed-citation>
</ref>
<ref id="bibr66-2398212819858249">
<mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Olsen</surname><given-names>RW</given-names></name><name><surname>Sieghart</surname><given-names>W</given-names></name></person-group> (<year>2008</year>) <article-title>International union of pharmacology: LXX – Subtypes of γ-aminobutyric acid<sub>A</sub></article-title>
<publisher-loc>receptors</publisher-loc>: <publisher-name>Classification on the basis of subunit composition, pharmacology, and function – Update</publisher-name>
<source/>Pharmacological Reviews
<volume>60</volume>(<issue>3</issue>): <fpage>243</fpage>–<lpage>260</lpage>.<pub-id pub-id-type="pmid">18790874</pub-id></mixed-citation>
</ref>
<ref id="bibr67-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Olsen</surname><given-names>RW</given-names></name><name><surname>Sieghart</surname><given-names>W</given-names></name></person-group> (<year>2009</year>) <article-title>GABA<sub>A</sub> receptors: Subtypes provide diversity of function and pharmacology</article-title>. <source/>Neuropharmacology
<volume>56</volume>(<issue>1</issue>): <fpage>141</fpage>–<lpage>148</lpage>.<pub-id pub-id-type="pmid">18760291</pub-id></mixed-citation>
</ref>
<ref id="bibr68-2398212819858249">
<mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Phulera</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal> (<year>2018</year>) <article-title>Cryo-EM structure of the benzodiazepine-sensitive α1β1γ2S tri-heteromeric GABA<sub>A</sub> receptor in complex with GABA</article-title>. <source/>Elife
<volume>7</volume>: <publisher-name>e39383</publisher-name>.</mixed-citation>
</ref>
<ref id="bibr69-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Picton</surname><given-names>AJ</given-names></name><name><surname>Fisher</surname><given-names>JL</given-names></name></person-group> (<year>2007</year>) <article-title>Effect of the α subunit subtype on the macroscopic kinetic properties of recombinant GABA<sub>A</sub> receptors</article-title>. <source/>Brain Research
<volume>1165</volume>: <fpage>40</fpage>–<lpage>49</lpage>.<pub-id pub-id-type="pmid">17658489</pub-id></mixed-citation>
</ref>
<ref id="bibr70-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pritchett</surname><given-names>DB</given-names></name><name><surname>Sontheimer</surname><given-names>H</given-names></name><name><surname>Shivers</surname><given-names>BD</given-names></name></person-group>, <etal>et al</etal> (<year>1989</year>) <article-title>Importance of a novel GABA<sub>A</sub> receptor subunit for benzodiazepine pharmacology</article-title>. <source/>Nature
<volume>338</volume>(<issue>6216</issue>): <fpage>582</fpage>–<lpage>585</lpage>.<pub-id pub-id-type="pmid">2538761</pub-id></mixed-citation>
</ref>
<ref id="bibr71-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Quick</surname><given-names>MW</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name></person-group>, <etal>et al</etal> (<year>2004</year>) <article-title>Regulation of a gamma-aminobutyric acid transporter by reciprocal tyrosine and serine phosphorylation</article-title>. <source/>The Journal of Biological Chemistry
<volume>279</volume>(<issue>16</issue>): <fpage>15961</fpage>–<lpage>15967</lpage>.<pub-id pub-id-type="pmid">14761965</pub-id></mixed-citation>
</ref>
<ref id="bibr72-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Roberts</surname><given-names>E</given-names></name><name><surname>Frankel</surname><given-names>S</given-names></name></person-group> (<year>1950</year>) <article-title>gamma-Aminobutyric acid in brain: its formation from glutamic acid</article-title>. <source/>The Journal of Biological Chemistry
<volume>187</volume>(<issue>1</issue>): <fpage>55</fpage>–<lpage>63</lpage>.<pub-id pub-id-type="pmid">14794689</pub-id></mixed-citation>
</ref>
<ref id="bibr73-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rudolph</surname><given-names>U</given-names></name><name><surname>Antkowiak</surname><given-names>B</given-names></name></person-group> (<year>2004</year>) <article-title>Molecular and neuronal substrates for general anaesthetics</article-title>. <source/>Nature Reviews: Neuroscience
<volume>5</volume>(<issue>9</issue>): <fpage>709</fpage>–<lpage>720</lpage>.<pub-id pub-id-type="pmid">15322529</pub-id></mixed-citation>
</ref>
<ref id="bibr74-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rudolph</surname><given-names>U</given-names></name><name><surname>Mohler</surname><given-names>H</given-names></name></person-group> (<year>2004</year>) <article-title>Analysis of GABA<sub>A</sub> receptor function and dissection of the pharmacology of benzodiazepines and general anesthetics through mouse genetics</article-title>. <source/>Annual Review of Pharmacology and Toxicology
<volume>44</volume>: <fpage>475</fpage>–<lpage>498</lpage>.</mixed-citation>
</ref>
<ref id="bibr75-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rudolph</surname><given-names>U</given-names></name><name><surname>Mohler</surname><given-names>H</given-names></name></person-group> (<year>2014</year>) <article-title>GABA<sub>A</sub> receptor subtypes: Therapeutic potential in Down syndrome, affective disorders, schizophrenia, and autism</article-title>. <source/>Annual Review of Pharmacology and Toxicology
<volume>54</volume>: <fpage>483</fpage>–<lpage>507</lpage>.</mixed-citation>
</ref>
<ref id="bibr76-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rudolph</surname><given-names>U</given-names></name><name><surname>Crestani</surname><given-names>F</given-names></name><name><surname>Benke</surname><given-names>D</given-names></name></person-group>, <etal>et al</etal> (<year>1999</year>) <article-title>Benzodiazepine actions mediated by specific gamma-aminobutyric acidA receptor subtypes</article-title>. <source/>Nature
<volume>401</volume>(<issue>6755</issue>): <fpage>796</fpage>–<lpage>800</lpage>.<pub-id pub-id-type="pmid">10548105</pub-id></mixed-citation>
</ref>
<ref id="bibr77-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sagne</surname><given-names>C</given-names></name><name><surname>El</surname><given-names>MS</given-names></name><name><surname>Isambert</surname><given-names>MF</given-names></name></person-group>, <etal>et al</etal> (<year>1997</year>) <article-title>Cloning of a functional vesicular GABA and glycine transporter by screening of genome databases</article-title>. <source/>FEBS Letters
<volume>417</volume>(<issue>2</issue>): <fpage>177</fpage>–<lpage>183</lpage>.<pub-id pub-id-type="pmid">9395291</pub-id></mixed-citation>
</ref>
<ref id="bibr78-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schofield</surname><given-names>PR</given-names></name><name><surname>Darlison</surname><given-names>MG</given-names></name><name><surname>Fujita</surname><given-names>N</given-names></name></person-group>, <etal>et al</etal> (<year>1987</year>) <article-title>Sequence and functional expression of the GABA<sub>A</sub> receptor shows a ligand-gated receptor super-family</article-title>. <source/>Nature
<volume>328</volume>(<issue>6127</issue>): <fpage>221</fpage>–<lpage>227</lpage>.<pub-id pub-id-type="pmid">3037384</pub-id></mixed-citation>
</ref>
<ref id="bibr79-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Scholfield</surname><given-names>CN</given-names></name></person-group> (<year>1978</year>) <article-title>A barbiturate induced intensification of the inhibitory potential in slices of guinea-pig olfactory cortex</article-title>. <source/>The Journal of Physiology
<volume>275</volume>(<issue>1</issue>): <fpage>559</fpage>–<lpage>566</lpage>.<pub-id pub-id-type="pmid">633156</pub-id></mixed-citation>
</ref>
<ref id="bibr80-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Scholfield</surname><given-names>CN</given-names></name></person-group> (<year>1980</year>) <article-title>Potentiation of inhibition by general anaesthetics in neurones of the olfactory cortex in vitro</article-title>. <source/>Pflügers Archiv
<volume>383</volume>(<issue>3</issue>): <fpage>249</fpage>–<lpage>255</lpage>.<pub-id pub-id-type="pmid">7190680</pub-id></mixed-citation>
</ref>
<ref id="bibr81-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Scimemi</surname><given-names>A</given-names></name></person-group> (<year>2014</year>) <article-title>Structure, function, and plasticity of GABA transporters</article-title>. <source/>Frontiers in Cellular Neuroscience
<volume>8</volume>: <fpage>161</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fncel.2014.00161</pub-id><pub-id pub-id-type="pmid">24987330</pub-id></mixed-citation>
</ref>
<ref id="bibr82-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Seeburg</surname><given-names>PH</given-names></name><name><surname>Wisden</surname><given-names>W</given-names></name><name><surname>Verdoorn</surname><given-names>TA</given-names></name></person-group>, <etal>et al</etal> (<year>1990</year>) <article-title>The GABA<sub>A</sub> receptor family: Molecular and functional diversity</article-title>. <source/>Cold Spring Harbor Symposia on Quantitative Biology
<volume>55</volume>: <fpage>29</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="pmid">1966765</pub-id></mixed-citation>
</ref>
<ref id="bibr83-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sieghart</surname><given-names>W</given-names></name></person-group> (<year>1995</year>) <article-title>Structure and pharmacology of gamma-Aminobutyric acidA receptor subtypes</article-title>. <source/>Pharmacological Reviews
<volume>47</volume>(<issue>2</issue>): <fpage>181</fpage>–<lpage>234</lpage>.<pub-id pub-id-type="pmid">7568326</pub-id></mixed-citation>
</ref>
<ref id="bibr84-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sigel</surname><given-names>E</given-names></name></person-group> (<year>2002</year>) <article-title>Mapping of the benzodiazepine recognition site on GABA<sub>A</sub> receptors</article-title>. <source/>Current Topics in Medicinal Chemistry
<volume>2</volume>(<issue>8</issue>): <fpage>833</fpage>–<lpage>839</lpage>.<pub-id pub-id-type="pmid">12171574</pub-id></mixed-citation>
</ref>
<ref id="bibr85-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sigel</surname><given-names>E</given-names></name><name><surname>Steinmann</surname><given-names>ME</given-names></name></person-group> (<year>2012</year>) <article-title>Structure, function, and modulation of GABA<sub>A</sub> receptors</article-title>. <source/>The Journal of Biological Chemistry
<volume>287</volume>(<issue>48</issue>): <fpage>40224</fpage>–<lpage>40231</lpage>.<pub-id pub-id-type="pmid">23038269</pub-id></mixed-citation>
</ref>
<ref id="bibr86-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sigel</surname><given-names>E</given-names></name><name><surname>Mamalaki</surname><given-names>C</given-names></name><name><surname>Barnard</surname><given-names>EA</given-names></name></person-group> (<year>1982</year>) <article-title>Isolation of a GABA receptor from bovine brain using a benzodiazepine affinity column</article-title>. <source/>FEBS Letters
<volume>147</volume>(<issue>1</issue>): <fpage>45</fpage>–<lpage>48</lpage>.<pub-id pub-id-type="pmid">6291997</pub-id></mixed-citation>
</ref>
<ref id="bibr87-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sigel</surname><given-names>E</given-names></name><name><surname>Stephenson</surname><given-names>FA</given-names></name><name><surname>Mamalaki</surname><given-names>C</given-names></name></person-group>, <etal>et al</etal> (<year>1983</year>) <article-title>A gamma-aminobutyric acid/benzodiazepine receptor complex of bovine cerebral cortex</article-title>. <source/>The Journal of Biological Chemistry
<volume>258</volume>(<issue>11</issue>): <fpage>6965</fpage>–<lpage>6971</lpage>.<pub-id pub-id-type="pmid">6304068</pub-id></mixed-citation>
</ref>
<ref id="bibr88-2398212819858249">
<mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Smart</surname><given-names>TG</given-names></name></person-group> (<year>2015</year>) <article-title>GABA<sub>A</sub> receptors</article-title>. In:<person-group person-group-type="editor"><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Trudeau</surname><given-names>MC</given-names></name></person-group> (eds) <source/>Handbook of Ion Channels. <publisher-loc>Boca Raton, FL</publisher-loc>: <publisher-name>CRC Press</publisher-name>, pp. <fpage>345</fpage>–<lpage>359</lpage>.</mixed-citation>
</ref>
<ref id="bibr89-2398212819858249">
<mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Smart</surname><given-names>TG</given-names></name><name><surname>Paoletti</surname><given-names>P</given-names></name></person-group> (<year>2012</year>) <article-title>Synaptic neurotransmitter-gated receptors</article-title>. In: <person-group person-group-type="editor"><name><surname>Sheng</surname><given-names>M</given-names></name><name><surname>Sabatini</surname><given-names>BL</given-names></name><name><surname>Sudhof</surname><given-names>TC</given-names></name></person-group> (eds) <source/>The Synapse. <publisher-loc>New York</publisher-loc>: <publisher-name>Cold Spring Harbor Laboratory Press</publisher-name>, pp. <fpage>191</fpage>–<lpage>216</lpage>.</mixed-citation>
</ref>
<ref id="bibr90-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Smart</surname><given-names>TG</given-names></name><name><surname>Constanti</surname><given-names>A</given-names></name><name><surname>Bilbe</surname><given-names>G</given-names></name></person-group>, <etal>et al</etal> (<year>1983</year>) <article-title>Synthesis of functional chick brain GABA-benzodiazepine-barbiturate/receptor complexes in mRNA-injected Xenopus oocytes</article-title>. <source/>Neurosci Letters
<volume>40</volume>(<issue>1</issue>): <fpage>55</fpage>–<lpage>59</lpage>.</mixed-citation>
</ref>
<ref id="bibr91-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Smart</surname><given-names>TG</given-names></name><name><surname>Houamed</surname><given-names>KM</given-names></name><name><surname>Van Renterghem</surname><given-names>C</given-names></name></person-group>, <etal>et al</etal> (<year>1987</year>) <article-title>mRNA-directed synthesis and insertion of functional amino acid receptors in Xenopus laevis Oocytes</article-title>. <source/>Biochemical Society Transactions
<volume>15</volume>(<issue>1</issue>): <fpage>117</fpage>–<lpage>122</lpage>.<pub-id pub-id-type="pmid">3030837</pub-id></mixed-citation>
</ref>
<ref id="bibr92-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stephenson</surname><given-names>FA</given-names></name></person-group> (<year>1995</year>) <article-title>The GABA<sub>A</sub> receptors</article-title>. <source/>The Biochemical Journal
<volume>310</volume>(<issue>Pt. 1</issue>): <fpage>1</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">7646429</pub-id></mixed-citation>
</ref>
<ref id="bibr93-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Unwin</surname><given-names>N</given-names></name></person-group> (<year>2005</year>) <article-title>Refined structure of the nicotinic acetylcholine receptor at 4Å resolution</article-title>. <source/>Journal of Molecular Biology
<volume>346</volume>(<issue>4</issue>): <fpage>967</fpage>–<lpage>989</lpage>.<pub-id pub-id-type="pmid">15701510</pub-id></mixed-citation>
</ref>
<ref id="bibr94-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Valeeva</surname><given-names>G</given-names></name><name><surname>Tressard</surname><given-names>T</given-names></name><name><surname>Mukhtarov</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal> (<year>2016</year>) <article-title>An optogenetic approach for investigation of excitatory and inhibitory network GABA actions in mice expressing channelrhodopsin-2 in GABAergic neurons</article-title>. <source/>The Journal of Neuroscience
<volume>36</volume>(<issue>22</issue>): <fpage>5961</fpage>–<lpage>5973</lpage>.<pub-id pub-id-type="pmid">27251618</pub-id></mixed-citation>
</ref>
<ref id="bibr95-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Varagic</surname><given-names>Z</given-names></name><name><surname>Wimmer</surname><given-names>L</given-names></name><name><surname>Schnurch</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal> (<year>2013</year>) <article-title>Identification of novel positive allosteric modulators and null modulators at the GABA<sub>A</sub> receptor α+β- interface</article-title>. <source/>British Journal of Pharmacology
<volume>169</volume>(<issue>2</issue>): <fpage>371</fpage>–<lpage>383</lpage>.<pub-id pub-id-type="pmid">23472852</pub-id></mixed-citation>
</ref>
<ref id="bibr96-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wafford</surname><given-names>KA</given-names></name><name><surname>Bain</surname><given-names>CJ</given-names></name><name><surname>Quirk</surname><given-names>K</given-names></name></person-group>, <etal>et al</etal> (<year>1994</year>) <article-title>A novel allosteric modulatory site on the GABA<sub>A</sub> receptor beta subunit</article-title>. <source/>Neuron
<volume>12</volume>(<issue>4</issue>): <fpage>775</fpage>–<lpage>782</lpage>.<pub-id pub-id-type="pmid">8161449</pub-id></mixed-citation>
</ref>
<ref id="bibr97-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>White</surname><given-names>JH</given-names></name><name><surname>Wise</surname><given-names>A</given-names></name><name><surname>Main</surname><given-names>MJ</given-names></name></person-group>, <etal>et al</etal> (<year>1998</year>) <article-title>Heterodimerization is required for the formation of a functional GABA<sub>B</sub> receptor</article-title>. <source/>Nature
<volume>396</volume>(<issue>6712</issue>): <fpage>679</fpage>–<lpage>682</lpage>.<pub-id pub-id-type="pmid">9872316</pub-id></mixed-citation>
</ref>
<ref id="bibr98-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Whitworth</surname><given-names>TL</given-names></name><name><surname>Quick</surname><given-names>MW</given-names></name></person-group> (<year>2001</year>) <article-title>Substrate-induced regulation of gamma-aminobutyric acid transporter trafficking requires tyrosine phosphorylation</article-title>. <source/>The Journal of Biological Chemistry
<volume>276</volume>(<issue>46</issue>): <fpage>42932</fpage>–<lpage>42937</lpage>.<pub-id pub-id-type="pmid">11555659</pub-id></mixed-citation>
</ref>
<ref id="bibr99-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yamasaki</surname><given-names>T</given-names></name><name><surname>Hoyos-Ramirez</surname><given-names>E</given-names></name><name><surname>Martenson</surname><given-names>JS</given-names></name></person-group>, <etal>et al</etal> (<year>2017</year>) <article-title>GARLH family proteins stabilize GABA<sub>A</sub> receptors at synapses</article-title>. <source/>Neuron
<volume>93</volume>(<issue>5</issue>): <fpage>1138</fpage>–<lpage>1152</lpage>.<pub-id pub-id-type="pmid">28279354</pub-id></mixed-citation>
</ref>
<ref id="bibr100-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yip</surname><given-names>GMS</given-names></name><name><surname>Chen</surname><given-names>ZW</given-names></name><name><surname>Edge</surname><given-names>CJ</given-names></name></person-group>, <etal>et al</etal> (<year>2013</year>) <article-title>A propofol binding site on mammalian GABA<sub>A</sub> receptors identified by photolabeling</article-title>. <source/>Nature Chemical Biology
<volume>9</volume>(<issue>11</issue>): <fpage>715</fpage>–<lpage>720</lpage>.<pub-id pub-id-type="pmid">24056400</pub-id></mixed-citation>
</ref>
<ref id="bibr101-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yuan</surname><given-names>H</given-names></name><name><surname>Low</surname><given-names>CM</given-names></name><name><surname>Moody</surname><given-names>OA</given-names></name></person-group>, <etal>et al</etal> (<year>2015</year>) <article-title>Ionotropic GABA and glutamate receptor mutations and human neurologic diseases</article-title>. <source/>Molecular Pharmacology
<volume>88</volume>(<issue>1</issue>): <fpage>203</fpage>–<lpage>217</lpage>.<pub-id pub-id-type="pmid">25904555</pub-id></mixed-citation>
</ref>
<ref id="bibr102-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yue</surname><given-names>L</given-names></name><name><surname>Pawlowski</surname><given-names>M</given-names></name><name><surname>Dellal</surname><given-names>SS</given-names></name></person-group>, <etal>et al</etal> (<year>2012</year>) <article-title>Robust photoregulation of GABA<sub>A</sub> receptors by allosteric modulation with a propofol analogue</article-title>. <source/>Nature Communications
<volume>3</volume>: <fpage>1095</fpage>. doi:<pub-id pub-id-type="doi">10.1038/ncomms2094</pub-id></mixed-citation>
</ref>
<ref id="bibr103-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zeilhofer</surname><given-names>HU</given-names></name><name><surname>Mohler</surname><given-names>H</given-names></name><name><surname>Di Lio</surname><given-names>A</given-names></name></person-group> (<year>2009</year>) <article-title>GABAergic analgesia: New insights from mutant mice and subtype-selective agonists</article-title>. <source/>Trends in Pharmacological Sciences
<volume>30</volume>(<issue>8</issue>): <fpage>397</fpage>–<lpage>402</lpage>.<pub-id pub-id-type="pmid">19616317</pub-id></mixed-citation>
</ref>
<ref id="bibr104-2398212819858249">
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhu</surname><given-names>S</given-names></name><name><surname>Noviello</surname><given-names>CM</given-names></name><name><surname>Teng</surname><given-names>J</given-names></name></person-group>, <etal>et al</etal> (<year>2018</year>) <article-title>Structure of a human synaptic GABA<sub>A</sub> receptor</article-title>. <source/>Nature
<volume>559</volume>(<issue>7712</issue>): <fpage>67</fpage>–<lpage>72</lpage>.<pub-id pub-id-type="pmid">29950725</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>